

Agenda

SATURDAY – September 22

7:00 AM Registration and Continental Breakfast

8:25 AM Welcome and Introductions.....*Eric Jonasch, MD*

PROSTATE CANCER

8:30 AM Pretest (Case Vignettes – ARS)*Eric Jonasch, MD / Amado Zurita, MD /
Sumit Subudhi, MD, PhD*

8:45 AM The Current Role of Systemic Therapy in Nonmetastatic Prostate Carcinoma*Eric Jonasch, MD*

9:15 AM Newly Diagnosed Metastatic Prostate Carcinoma:.....*Amado Zurita, MD*
Has The Paradigm Changed?

9:45 AM Immunotherapy in Prostate Cancer: Promises and Pitfalls *Sumit Subudhi, MD, PhD*

10:15 AM Posttest (Case Vignettes – ARS)*Eric Jonasch, MD / Amado Zurita, MD /
Sumit Subudhi, MD, PhD*

10:30 AM BREAK

RENAL CELL CARCINOMA

10:45 AM Pretest (Case Vignettes – ARS)*Hans Hammers, MD, PhD / Eric Jonasch, MD /
Nizar M. Tannir, MD*

11:00 AM Advances in Multitargeted Kinase Inhibitor in the Treatment*Hans Hammers, MD, PhD*
of Metastatic Renal Cell Carcinoma (RCC): Lenvatinib

11:30 AM Update on MET, AXL and VEGF Receptor Inhibitor in the*Eric Jonasch, MD*
Treatment of Metastatic RCC: Cabozantinib

12:00 PM LUNCH

1:00 PM Immunotherapy with Novel PD-1 Checkpoint Inhibitors and*Nizar M. Tannir, MD*
Targeted Therapy Combinations in the Treatment of RCC

1:30 PM Posttest (Case Vignettes – ARS)*Hans Hammers, MD, PhD / Eric Jonasch, MD /
Nizar M. Tannir, MD*

UROTHELIAL BLADDER CARCINOMA

1:45 PM Pretest (Case Vignettes – ARS) *Ashish M. Kamat, MD*

2:00 PM Genetic Alterations in the Molecular Subtypes of *Ashish M. Kamat, MD*
Urothelial Bladder Cancer (UBC)

2:30 PM BREAK

2:45 PM Update on Immunotherapy with PD-1/PD-L1 Antibodies in..... *Ashish M. Kamat, MD*
Patients with UBC

3:15 PM Posttest (Case Vignettes – ARS) *Ashish M. Kamat, MD*

3:30 PM Closing Comments and Adjourn.....*Eric Jonasch, MD*